Baili Tianheng (688506.SH): Iza-bren achieves the primary endpoint in the mid-term analysis of the Phase III clinical trial for recurrent or metastatic esophageal squamous cell carcinoma.

Toucai Finance APP News, Balitinuotianheng (688506.SH) announced that the EGFRHER3 bispecific ADC (iza-bren) developed independently by the company, the world's first (First-in-class), new concept (Newconcept), and the only one to enter Phase III clinical trials, has achieved both progression-free survival (PFS) and overall survival (OS) endpoints in the pre-specified interim analysis by the independent data monitoring committee (iDMC) in the Phase III clinical trial for esophageal squamous cell carcinoma (study protocol number: BL-B01D1-305), indication: recurrent or metastatic esophageal squamous cell carcinoma that has failed prior treatment with PD-1/PD-L1 monoclonal antibodies combined with platinum-based chemotherapy. This is the world's first Phase III clinical study of an ADC drug to achieve positive results in both PFS and OS in the treatment of esophageal cancer.